Roivant Sciences Ltd (NASDAQ:ROIV) Receives $13.33 Average Target Price from Brokerages

Roivant Sciences Ltd (NASDAQ:ROIV) has been assigned an average recommendation of “Buy” from the eight ratings firms that are currently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $13.33.

A number of brokerages have commented on ROIV. The Goldman Sachs Group began coverage on shares of Roivant Sciences in a research note on Wednesday, December 15th. They issued a “buy” rating and a $15.00 price target for the company. HC Wainwright began coverage on shares of Roivant Sciences in a research note on Monday, November 8th. They issued a “buy” rating and a $14.00 price target for the company. Truist Securities began coverage on shares of Roivant Sciences in a research note on Tuesday, October 26th. They issued a “buy” rating and a $15.00 price target for the company. Truist began coverage on shares of Roivant Sciences in a research note on Tuesday, October 26th. They issued a “buy” rating and a $15.00 price target for the company. Finally, SVB Leerink reiterated a “buy” rating on shares of Roivant Sciences in a research note on Sunday, December 5th.

Shares of ROIV opened at $7.95 on Friday. Roivant Sciences has a 12 month low of $5.80 and a 12 month high of $16.76. The stock’s fifty day simple moving average is $9.93.

Roivant Sciences (NASDAQ:ROIV) last announced its earnings results on Monday, November 15th. The company reported ($0.87) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.19. The business had revenue of $13.99 million for the quarter, compared to analyst estimates of $5.30 million. Analysts forecast that Roivant Sciences will post -1.02 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients. Roivant Sciences, formerly known as Montes Archimedes Acquisition Corp., is based in NEW YORK.

See Also: Cost Basis

Analyst Recommendations for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.